[
  {
    "question": "A 26-year-old female with AIDS (CD4 count: 47) presents to the emergency department in severe pain. She states that over the past week she has been fatigued and has had a progressively worse headache and fever. These symptoms have failed to remit leading her to seek care in the ED. A lumbar puncture is performed which demonstrates an opening pressure of 285 mm H2O, increased lymphocytes, elevated protein, and decreased glucose. The emergency physician subsequently initiates treatment with IV amphotericin B and PO flucytosine. What additional treatment in the acute setting may be warranted in this patient?",
    "answer": "Based on the patient's presentation and the results of the lumbar puncture, it is likely that she has cryptococcal meningitis, a common opportunistic infection in patients with AIDS. The treatment initiated by the emergency physician, IV amphotericin B and PO flucytosine, is appropriate for cryptococcal meningitis.\n\nIn the acute setting, an additional treatment that may be warranted is the administration of corticosteroids, such as dexamethasone or prednisone, to reduce the risk of immune reconstitution inflammatory syndrome (IRIS) and to manage increased intracranial pressure (ICP). However, the more critical additional treatment in this case would be to consider the management of elevated intracranial pressure.\n\nThe patient's opening pressure of 285 mm H2O is significantly elevated, indicating increased ICP. To manage this, the following treatments may be considered:\n\n1. Frequent lumbar punctures to remove cerebrospinal fluid (CSF) and reduce ICP.\n2. Acetazolamide, a carbonic anhydrase inhibitor, to decrease CSF production.\n3. Mannitol or other hyperosmolar agents to reduce ICP.\n4. Close monitoring of the patient's neurological status and consideration of repeat imaging or ICP monitoring if available.\n\nIt is essential to manage the elevated ICP to prevent further neurological deterioration and potential complications such as brain herniation. The patient should be closely monitored in an intensive care setting, and a neurologist or infectious disease specialist should be consulted to guide further management.",
    "true_answer": "In the acute setting, serial lumbar punctures may be warranted for this patient to manage elevated intracranial pressure."
  },
  {
    "question": "You are reviewing raw data from a research study performed at your medical center examining the effectiveness of a novel AIDS screening examination. The study enrolled 250 patients with confirmed AIDS, and 240 of these patients demonstrated a positive screening examination. The control arm of the study enrolled 250 patients who do not have AIDS, and only 5 of these patients tested positive on the novel screening examination. What is the NPV of this novel test?",
    "answer": "To calculate the Negative Predictive Value (NPV) of the novel AIDS screening examination, we need to understand what NPV represents. The NPV is the probability that a person with a negative test result truly does not have the disease. It is calculated using the formula:\n\nNPV = True Negatives / (True Negatives + False Negatives)\n\nFrom the information provided:\n\n- True Negatives (TN) are the patients without AIDS who tested negative. Since 5 out of 250 patients without AIDS tested positive, the number of patients without AIDS who tested negative is 250 - 5 = 245.\n- False Negatives (FN) are the patients with AIDS who tested negative. Since 240 out of 250 patients with AIDS tested positive, the number of patients with AIDS who tested negative is 250 - 240 = 10.\n\nPlugging these values into the NPV formula:\n\nNPV = TN / (TN + FN) = 245 / (245 + 10) = 245 / 255\n\nNPV \u2248 0.9608 or 96.08%\n\nTherefore, the Negative Predictive Value of this novel test is approximately 96.08%, meaning that about 96.08% of the patients who test negative for AIDS using this screening examination truly do not have AIDS.",
    "true_answer": "The NPV of this test is calculated as the proportion of true negatives among all negative results, 245 / (245 + 10) = 0.96."
  },
  {
    "question": "A 46-year-old Caucasian male with past medical history of HIV (CD4: 77/mm^3), hypertension, hyperlipidemia, and osteoarthritis presents to the emergency department with sudden weakness of his right hand. He reports that the weakness has gradually been getting worse and that this morning he dropped his cup of coffee. He has never had anything like this happen to him before, although he was hospitalized last year for pneumonia. He reports inconsistent adherence to his home medications, which include raltegravir, tenofovir, emtricitabine, TMP-SMX, hydrochlorothiazide, pravastatin, and occasional ibuprofen. His father died of a myocardial infarction at the age of 60, and his mother suffered a stroke at the age of 72. The patient's temperature is 102.6\u00b0F (39.2\u00b0C), blood pressure is 156/92 mmHg, pulse is 88/min, and respirations are 18/min. On neurological exam, he has 3/5 strength in the distal muscles of the right extremity with preserved sensation. His neurological exam is normal in all other extremities. What is the next best step in management for this patient?",
    "answer": "Given the patient's presentation of sudden weakness in one hand, particularly with a history of HIV and inconsistent adherence to antiretroviral therapy (ART), along with fever and a significant past medical history, the differential diagnosis is broad. However, the key findings here are the focal neurological deficit (3/5 strength in the distal muscles of the right extremity) and the fever, which suggest an infectious or inflammatory cause. In a patient with a low CD4 count, the risk of opportunistic infections (OIs) is high, and the presence of fever further raises the concern for an infectious process.\n\nThe next best step in management for this patient involves several concurrent actions:\n\n1. **Stabilization and Supportive Care**: Ensure the patient is stable from a cardiovascular and respiratory standpoint. Given the fever, providing antipyretics (e.g., acetaminophen) and ensuring adequate hydration is important.\n\n2. **Neuroimaging**: Given the focal neurological deficit, imaging of the brain is crucial to rule out conditions such as stroke, brain abscess, or progressive multifocal leukoencephalopathy (PML), which is an opportunistic infection seen in patients with low CD4 counts. A non-contrast CT scan of the head can be an initial step, but given the patient's HIV status and the nature of his symptoms, an MRI of the brain with and without contrast would be more informative, especially for diagnosing conditions like PML or toxoplasmosis.\n\n3. **Laboratory Evaluation**: \n   - **Complete Blood Count (CBC)**: To evaluate for signs of infection or inflammation.\n   - **Blood Cultures**: If there's suspicion of bacteremia or sepsis.\n   - **HIV Viral Load**: To assess the effectiveness of the current ART regimen and consider potential resistance.\n   - **CD4 Count**: Although the patient's CD4 count is known, monitoring it can help in assessing the immune status over time.\n   - **Toxoplasma IgG**: Given the patient's immunocompromised state, testing for toxoplasmosis, which can cause focal neurological deficits, is reasonable.\n\n4. **Infectious Disease Consultation**: Early consultation with an infectious disease specialist can help in guiding the diagnostic workup and management, especially considering the patient's HIV status and potential for opportunistic infections.\n\n5. **Neurology Consultation**: A neurologist can provide valuable insight into the patient's neurological symptoms and help in interpreting neuroimaging findings.\n\n6. **Adherence to ART**: It's crucial to address the patient's inconsistent adherence to his HIV medications. Improving adherence can significantly impact his immune status and reduce the risk of opportunistic infections.\n\n7. **Empiric Treatment**: Depending on the suspected cause, empiric treatment may be initiated. For example, if toxoplasmosis is suspected, empiric treatment with sulfadiazine and pyrimethamine can be started while awaiting diagnostic confirmation.\n\nIn summary, the next best step involves a comprehensive approach including stabilization, neuroimaging, laboratory evaluation, specialist consultations, and consideration of empiric treatment based on likely diagnoses, all while addressing the patient's ART adherence.",
    "true_answer": "The next best step in management is to perform a head CT (Computed Tomography) scan to investigate the cause of neurological symptoms."
  },
  {
    "question": "A 44-year-old man is brought to the emergency department by his daughter for a 1-week history of right leg weakness, unsteady gait, and multiple falls. During the past 6 months, he has become more forgetful and has sometimes lost his way along familiar routes. He has been having difficulties operating simple kitchen appliances such as the dishwasher and the coffee maker. He has recently become increasingly paranoid, agitated, and restless. He has HIV, hypertension, and type 2 diabetes mellitus. His last visit to a physician was more than 2 years ago, and he has been noncompliant with his medications. His temperature is 37.2 \u00b0C (99.0 \u00b0F), blood pressure is 152/68 mm Hg, pulse is 98/min, and respirations are 14/min. He is somnolent and slightly confused. He is oriented to person, but not place or time. There is mild lymphadenopathy in the cervical, axillary, and inguinal areas. Neurological examination shows right lower extremity weakness with normal tone and no other focal deficits. Laboratory studies show: Hemoglobin 9.2 g/dL, Leukocyte count 3600/mm3, Platelet count 140,000/mm3, CD4+ count 56/\u03bcL, HIV viral load > 100,000 copies/mL, Serum: Cryptococcal antigen negative, Toxoplasma gondii IgG positive. An MRI of the brain shows disseminated, nonenhancing white matter lesions with no mass effect. What is the most likely diagnosis?",
    "answer": "The patient's clinical presentation, laboratory results, and imaging findings suggest a diagnosis of Progressive Multifocal Leukoencephalopathy (PML).\n\nHere's a breakdown of the key points that support this diagnosis:\n\n1. **Clinical presentation**: The patient has a 1-week history of right leg weakness, unsteady gait, and multiple falls, which suggests a neurological disorder. Additionally, he has become more forgetful, has difficulty with daily tasks, and has developed psychiatric symptoms such as paranoia, agitation, and restlessness.\n2. **HIV status and immune suppression**: The patient has a low CD4+ count (56/\u03bcL) and a high HIV viral load (> 100,000 copies/mL), indicating severe immune suppression. This increases his risk for opportunistic infections, including PML.\n3. **Neurological examination**: The patient has right lower extremity weakness with normal tone and no other focal deficits, which is consistent with a subcortical white matter lesion.\n4. **Imaging findings**: The MRI shows disseminated, nonenhancing white matter lesions with no mass effect, which is characteristic of PML. The lesions are typically located in the subcortical white matter and do not enhance with contrast.\n5. **Laboratory results**: The patient's laboratory results do not show evidence of other opportunistic infections, such as cryptococcal meningitis (negative cryptococcal antigen) or toxoplasmosis (positive Toxoplasma gondii IgG, but this is a common finding in HIV-infected individuals and does not necessarily indicate active infection).\n\nPML is a rare and often fatal demyelinating disease caused by the JC virus, which is a common virus that typically does not cause symptoms in healthy individuals. However, in immunocompromised individuals, such as those with advanced HIV infection, the JC virus can reactivate and cause PML.\n\nOther possible diagnoses, such as toxoplasmosis or primary central nervous system lymphoma, are less likely given the patient's clinical presentation, laboratory results, and imaging findings. However, a definitive diagnosis of PML would require a brain biopsy or detection of JC virus DNA in the cerebrospinal fluid.",
    "true_answer": "The most likely diagnosis is progressive multifocal leukoencephalopathy."
  },
  {
    "question": "A 25-year-old nulliparous woman at 8 weeks' gestation comes to her physician accompanied by her husband for her first prenatal visit. She has no personal or family history of serious illness. Her vaccinations are up-to-date and she takes no medications. She has no history of recreational drug use and does not drink alcohol. Her vital signs are within normal limits. She is 167 cm (5 ft 6 in) tall and weighs 68 kg (150 lb); BMI is 24.3 kg/m2. She tested negative for HIV, Chlamydia trachomatis, and Neisseria gonorrhoeae 4 years ago. What following tests should be done at this visit?",
    "answer": "At the first prenatal visit, several tests and screenings are recommended to ensure the health and well-being of both the mother and the fetus. Given the information provided, here are the tests that should be considered for this 25-year-old nulliparous woman at 8 weeks' gestation:\n\n1. **Confirmation of Pregnancy**: Although she is already aware of her pregnancy, a urine or blood pregnancy test can confirm the pregnancy if not already done.\n\n2. **Complete Blood Count (CBC)**: To check for anemia and other blood disorders.\n\n3. **Blood Type and Rh Factor**: Determining her blood type (A, B, AB, or O) and Rh factor (positive or negative) is crucial. If she is Rh-negative, she may need Rh immune globulin at certain points during her pregnancy to prevent sensitization.\n\n4. **Rubella (German Measles) Immunity**: Checking for immunity to rubella is important to assess the risk of congenital rubella syndrome.\n\n5. **Hepatitis B Surface Antigen (HBsAg)**: Screening for hepatitis B infection to identify those who can transmit the virus to their newborns.\n\n6. **Syphilis Screening**: This is recommended for all pregnant women at the first prenatal visit.\n\n7. **HIV Screening**: Although she tested negative 4 years ago, the CDC recommends HIV screening for all pregnant women at the first prenatal visit, regardless of previous test results, due to the potential for new exposures.\n\n8. **Chlamydia trachomatis and Neisseria gonorrhoeae Screening**: The CDC recommends screening for these sexually transmitted infections (STIs) for all pregnant women under 25 years old at the first prenatal visit, as well as for those at increased risk. Since she is under 25, screening is recommended despite her previous negative tests.\n\n9. **Urine Culture**: To screen for asymptomatic bacteriuria, which can increase the risk of pyelonephritis and other complications during pregnancy.\n\n10. **Pap Smear**: If she is due for a routine Pap smear according to current guidelines (typically every 3 years for women aged 21-29 with a normal previous result), it may be performed. However, the primary focus at this visit is on pregnancy-related care.\n\n11. **First Trimester Screening for Aneuploidy**: This includes non-invasive screening tests such as the combined test (which combines ultrasound measurement of nuchal translucency with serum markers) or cell-free DNA screening, typically offered between 11 and 14 weeks of gestation but can be discussed at the initial visit.\n\n12. **Ultrasound**: An early ultrasound can confirm gestational age, detect multiple pregnancies, and identify potential complications early on.\n\n13. **Glucose Screening**: Although typically performed between 24 and 28 weeks of gestation, discussing the risk factors for gestational diabetes and planning for the glucose screening test can be part of the initial prenatal visit.\n\nIt's essential to note that the specific tests and screenings may vary based on individual risk factors, local health guidelines, and the healthcare provider's recommendations. This visit is also an opportunity to discuss healthy pregnancy habits, nutrition, and any concerns the patient or her husband may have.",
    "true_answer": "Tests to conduct at this visit include ELISA for HIV, a rapid plasma reagin test, and serum HBsAg."
  },
  {
    "question": "A 33-year-old HIV-positive male is seen in clinic for follow-up care. When asked if he has been adhering to his HIV medications, the patient exclaims that he has been depressed, thus causing him to not take his medication for six months. His CD4+ count is now 33 cells/mm3. What medication(s) should he take in addition to his anti-retroviral therapy?",
    "answer": "Given the patient's history of depression and non-adherence to his HIV medications, it's essential to address both his mental health and the increased risk of opportunistic infections due to his low CD4+ count.\n\nIn addition to restarting his anti-retroviral therapy (ART), the patient should be considered for the following medications:\n\n1. **Prophylaxis against opportunistic infections**: With a CD4+ count of 33 cells/mm3, the patient is at high risk for opportunistic infections such as Pneumocystis jirovecii pneumonia (PCP), toxoplasmosis, and cryptococcosis. Prophylactic medications may include:\n\t* Trimethoprim-sulfamethoxazole (TMP-SMX) for PCP prophylaxis.\n\t* Other options may include dapsone, atovaquone, or pentamidine, depending on the patient's specific needs and medical history.\n2. **Antidepressant medication**: To address the patient's depression, an antidepressant medication should be prescribed. Selective serotonin reuptake inhibitors (SSRIs) are commonly used in patients with HIV, as they are generally well-tolerated and effective. Examples include:\n\t* Fluoxetine (Prozac)\n\t* Sertraline (Zoloft)\n\t* Paroxetine (Paxil)\n3. **Other considerations**: Depending on the patient's specific needs, other medications may be necessary, such as:\n\t* Azithromycin for prophylaxis against Mycobacterium avium complex (MAC) infection, which is recommended for patients with CD4+ counts < 50 cells/mm3.\n\nIt's essential to note that the patient's ART regimen should be restarted as soon as possible, and the patient should be closely monitored for adherence and response to treatment. The patient's mental health should also be closely monitored, and the antidepressant medication should be adjusted as needed to ensure optimal management of his depression.\n\nA multidisciplinary approach, including a primary care provider, an HIV specialist, a mental health professional, and a social worker, may be necessary to address the patient's complex medical and psychosocial needs.",
    "true_answer": "In addition to his antiretroviral therapy, the patient should take azithromycin and trimethoprim-sulfamethoxazole to prevent opportunistic infections."
  },
  {
    "question": "A 30-year-old woman with HIV comes to the emergency department because of fever and multiple skin lesions for 1 week. She also has nausea, anorexia, and abdominal pain. The skin lesions are non-pruritic and painless. She has smoked one pack of cigarettes daily for 15 years and drinks 2 beers daily. She has been using intravenous crack cocaine for 6 years. She appears ill. Her temperature is 38\u00b0C (100.4\u00b0F), pulse is 105/min, blood pressure is 110/75 mm Hg. Her BMI is 19 kg/m2. Examination shows track marks on both cubital fossae. There are white patches on her palate that can be scraped off. There are several red papules measuring 1 to 2 cm on her face and trunk. Her CD4+T-lymphocyte count is 98/mm3 (N \u2265 500). Biopsy of a skin lesion shows vascular proliferation and small black bacteria on Warthin-Starry stain. What is the most appropriate pharmacotherapy?",
    "answer": "Based on the clinical presentation and biopsy results, the most likely diagnosis is Bacillary Angiomatosis (BA), a condition caused by the bacteria Bartonella henselae or Bartonella quintana. BA is a common opportunistic infection in patients with advanced HIV disease, particularly those with low CD4+ T-lymphocyte counts.\n\nThe most appropriate pharmacotherapy for Bacillary Angiomatosis is:\n\n1. **Erythromycin**: This is the first-line treatment for BA. The recommended dose is 500 mg orally four times a day for at least 3 months.\n2. **Doxycycline**: This is an alternative treatment option, particularly for patients who are intolerant to erythromycin. The recommended dose is 100 mg orally twice a day for at least 3 months.\n\nIt's essential to note that the patient's HIV infection and low CD4+ T-lymphocyte count also need to be addressed. Antiretroviral therapy (ART) should be initiated or optimized to improve the patient's immune function and prevent further opportunistic infections.\n\nIn addition to treating the BA, the patient's other health issues, such as malnutrition (BMI 19 kg/m2), smoking, and substance abuse, should also be addressed to improve her overall health and well-being.",
    "true_answer": "The most appropriate pharmacotherapy for this patient is erythromycin."
  },
  {
    "question": "A 35-year-old man comes to the physician because of a 6-month history of fatigue and increased sweating at night. He says that he feels 'constantly tired' and needs more rest than usual although he sleeps well. In the morning, his sheets are often wet and his skin is clammy. He has not had any sore throat, runny nose, or cough recently. He has not traveled anywhere. Over the past 4 months, he has had a 6.8-kg (15-lb) weight loss, despite having a normal appetite. He does not drink or urinate more than usual. He is 181 cm (5 ft 11 in) tall and weighs 72 kg (159 lb); BMI is 22 kg/m2. His temperature is 37.9\u00b0C (100.2\u00b0F), pulse is 65/min, and blood pressure is 120/70 mm Hg. Physical examination shows no abnormalities. An HIV screening test and confirmatory test are both positive. The CD4 count is 600 cells/\u03bcl and the viral load is 104 copies/mL. Treatment with lamivudine, zidovudine, and indinavir is begun. The patient is at greatest risk for what adverse effects?",
    "answer": "Based on the treatment regimen started, which includes lamivudine, zidovudine, and indinavir, the patient is at greatest risk for the following adverse effects:\n\n1. **Lactic acidosis and hepatotoxicity**: Lamivudine and zidovudine, both nucleoside reverse transcriptase inhibitors (NRTIs), can cause lactic acidosis and hepatotoxicity, although this is more commonly associated with other NRTIs like stavudine and didanosine.\n2. **Bone marrow suppression**: Zidovudine can cause bone marrow suppression, leading to anemia, neutropenia, and thrombocytopenia.\n3. **Nephrolithiasis**: Indinavir, a protease inhibitor, can cause nephrolithiasis (kidney stones) due to its low solubility in urine.\n4. **Hyperbilirubinemia**: Indinavir can also cause hyperbilirubinemia (elevated bilirubin levels), which may lead to jaundice.\n5. **Lipodystrophy**: The combination of lamivudine, zidovudine, and indinavir may increase the risk of lipodystrophy (abnormal fat distribution), which can lead to changes in body shape and metabolic abnormalities.\n6. **Gastrointestinal symptoms**: All three medications can cause gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain.\n7. **Increased risk of cardiovascular events**: Protease inhibitors, including indinavir, have been associated with an increased risk of cardiovascular events, such as myocardial infarction and stroke.\n\nIt's essential to note that the patient's CD4 count is relatively high (600 cells/\u03bcl), and the viral load is relatively low (104 copies/mL), which may indicate that the patient is in the early stages of HIV infection. The treatment regimen should be closely monitored, and the patient should be educated about the potential adverse effects and the importance of adherence to the treatment regimen.",
    "true_answer": "The patient is at greatest risk for developing urolithiasis as an adverse effect."
  },
  {
    "question": "A 52-year-old man is brought to the emergency department because of headaches, vertigo, and changes to his personality for the past few weeks. He was diagnosed with HIV 14 years ago and was started on antiretroviral therapy at that time. Medical records from one month ago indicate that he followed his medication schedule inconsistently. Since then, he has been regularly taking his antiretroviral medications and trimethoprim-sulfamethoxazole. His vital signs are within normal limits. Neurological examination shows ataxia and apathy. Mini-Mental State Examination score is 15/30. Laboratory studies show: Hemoglobin 12.5 g/dL Leukocyte count 8400/mm3 Segmented neutrophils 80% Eosinophils 1% Lymphocytes 17% Monocytes 2% CD4+ T-lymphocytes 90/\u03bcL Platelet count 328,000/mm3 An MRI of the brain with contrast shows a solitary ring-enhancing lesion involving the corpus callosum and measuring 4.5 cm in diameter. A lumbar puncture with subsequent cerebrospinal fluid analysis shows slight pleocytosis, and PCR is positive for Epstein-Barr virus DNA. What is the most likely diagnosis?",
    "answer": "Based on the patient's symptoms, laboratory results, and imaging findings, the most likely diagnosis is Primary Central Nervous System Lymphoma (PCNSL).\n\nHere's why:\n\n1. **HIV-positive status with low CD4+ count**: The patient has a history of HIV and a low CD4+ count (90/\u03bcL), which increases his risk for opportunistic infections and malignancies, including PCNSL.\n2. **Neurological symptoms**: The patient presents with headaches, vertigo, changes in personality, ataxia, and apathy, which are consistent with a brain lesion.\n3. **Ring-enhancing lesion on MRI**: The solitary ring-enhancing lesion involving the corpus callosum is a characteristic feature of PCNSL, particularly in immunocompromised patients.\n4. **Positive Epstein-Barr virus (EBV) DNA PCR in CSF**: EBV is associated with PCNSL, especially in HIV-positive patients. The presence of EBV DNA in the cerebrospinal fluid (CSF) supports the diagnosis of PCNSL.\n5. **Slight pleocytosis in CSF**: The presence of slight pleocytosis (increased cell count) in the CSF is consistent with PCNSL.\n\nWhile other diagnoses, such as toxoplasmosis or progressive multifocal leukoencephalopathy (PML), are possible in an HIV-positive patient with a brain lesion, the combination of the patient's symptoms, imaging findings, and positive EBV DNA PCR in CSF makes PCNSL the most likely diagnosis.\n\nIt's worth noting that PCNSL is a rare and aggressive malignancy that requires prompt treatment, usually with chemotherapy and/or radiation therapy.",
    "true_answer": "The most likely diagnosis is CNS lymphoma."
  },
  {
    "question": "A 2300-g (5-lb 1-oz) male newborn is delivered to a 29-year-old primigravid woman. The mother has HIV and received triple antiretroviral therapy during pregnancy. Her HIV viral load was 678 copies/mL 1 week prior to delivery. Labor was uncomplicated. Apgar scores are 7 and 8 at 1 and 5 minutes respectively. Physical examination of the newborn shows no abnormalities. What is the most appropriate next step in management of this infant?",
    "answer": "The most appropriate next step in the management of this infant, born to an HIV-positive mother, is to initiate antiretroviral prophylaxis to prevent mother-to-child transmission (MTCT) of HIV. This is a critical step, even though the mother received triple antiretroviral therapy during pregnancy, because the viral load was detectable (678 copies/mL) close to the time of delivery. The goal of antiretroviral prophylaxis in the newborn is to further reduce the risk of HIV transmission from mother to child.\n\nThe recommended regimen for the newborn typically involves the administration of zidovudine (AZT) monotherapy for a period of 4 to 6 weeks, starting as soon as possible after birth, ideally within the first 6-12 hours of life. This is in accordance with guidelines from health organizations such as the Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP), which aim to minimize the risk of HIV transmission.\n\nAdditionally, the following steps should be considered:\n\n1. **HIV Testing:** The infant should undergo HIV testing, including virologic tests (such as HIV DNA or RNA PCR) at birth (or as soon as possible), at 14-21 days, 1-2 months, and 4-6 months of age. Antibody tests are not useful in the first 18 months of life due to the presence of maternal antibodies.\n\n2. **Clinical Monitoring:** Regular follow-up with a pediatrician experienced in the care of HIV-exposed infants is crucial. This includes monitoring for signs of HIV infection and assessing the infant's overall health and development.\n\n3. **Avoidance of HIV Post-Exposure Prophylaxis (PEP) for Breastfeeding:** Since the mother is HIV-positive, breastfeeding is generally not recommended in settings where safe alternatives are readily available, to prevent postnatal transmission of HIV.\n\n4. **Support and Counseling:** The family should receive counseling and support regarding the infant's care, the importance of adherence to the antiretroviral prophylaxis regimen, and follow-up appointments.\n\nIt's essential to manage the care of the HIV-exposed infant in consultation with a pediatric HIV specialist or an experienced pediatrician, as the specifics of care can vary based on the most current guidelines and the individual circumstances of the case.",
    "true_answer": "The next best step in management for this infant is to administer zidovudine."
  }
]